

May 14, 2026

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

Scrip Code: 531015

Subject: Submission of Audited Standalone Financial Results along with Auditors' Report for the quarter and year ended 31st March, 2026

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Audited Standalone Financial Results along with Auditors' Report with unmodified opinion for the quarter and financial year ended 31st March, 2026.

The Financial Results are also available on the website of the Company at www.venmaxdrugs.com and on the website of BSE www.bseindia.com.

The Board Meeting commenced at 3:30 P.M. and concluded at 05:00 P.M.

Kindly take the above information on record and oblige.

Thanking You

Yours Faithfully

for **Venmax Drugs & Pharmaceuticals Limited**

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Statement of Financial Results for the Quarter and Year ended 31st March 2026

(Rs. In Lakhs)

Particulars		Quarter ended			Year Ended	
		31/03/2026 (Audited)	31/12/2025 (Unaudited)	31/03/2025 (Audited)	31/03/2026 (Audited)	31/03/2025 (Audited)
Income						
I	Revenue from operations	394.39	155.23	33.28	802.49	80.73
II	Other income	9.21	6.83	102.32	16.04	105.32
	Total Revenue (I+II)	403.60	162.06	135.60	818.53	186.05
Expenses						
	Cost of materials consumed	-	-	-	-	-
	Purchases of Stock-in-Trade	306.32	145.29	33.27	822.27	85.21
	Change of Inventory	57.27	(4.25)	(5.75)	(94.13)	(5.75)
	Employee benefits expense	5.43	3.47	2.60	19.67	4.00
	Finance costs	-	-	-	-	-
	Depreciation and amortization expense	0.10	0.10	0.16	0.40	0.64
	Other expenses	24.05	13.16	27.83	42.64	103.35
	Total expenses	393.16	157.77	58.11	790.83	187.46
III	Profit before Exceptional items and tax	10.44	4.29	77.48	27.70	(1.41)
	Exceptional Items					
	Profit / (Loss) before tax	10.44	4.29	77.48	27.70	(1.41)
IV	Tax expense:					
	Current tax	(0.28)	1.08	-	2.88	-
	Deferred tax	(0.00)	(0.00)	(0.33)	(0.01)	(0.36)
	Profit/(loss) for the period from continuing operations	(0.28)	1.08	(0.33)	2.88	(0.36)
	Profit/(loss) from discontinued operations					
	Tax expense of discontinued operations					
	Profit/(loss) from Discontinued operations (After tax)					
V	Profit/(loss) for the year	10.72	3.21	77.81	24.82	(1.05)
	Other Comprehensive Income					
	A (i) Items that will not be reclassified to Profit or Loss					
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss					
	B (i) Items that will be reclassified to Profit or Loss					
	(ii) Income tax relating to items that will be reclassified to Profit or Loss					
	Total Comprehensive Incoe for the period (Comprising Profit / (Loss)) and					

	Other Comprehensive Income for the period)					
VI	Earnings per Equity Share - Basic and Diluted	0.205	0.06	1.49	0.21	(0.02)

Notes to Accounts:

1. The above audited standalone financial results of VENMAX DRUGS AND PHARMACEUTICALS LIMITED for the quarter ended and year ended 31st March, 2026 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th May, 2026. The Statutory Auditors of the Company have carried out an audit of the standalone financial results and have expressed an unmodified opinion thereon.
2. The Financial results have been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standard) Rules, 20105 (Ind AS), and other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India (SEBI).
3. The Company operates in single segment. Accordingly, disclosures under Indian Accounting Standards (Ind AS) 108 on operating segments are not applicable to the Company.
4. Previous period figures have been reclassified and regrouped wherever considered necessary to confirm to the current period figures.
5. During the Year the company converted 63,44,000 share warrants in to Equity at a Face value of Rs.10 and at a premium of Rs.10/- each.

Place: Hyderabad
Date: 14th May 2026

For Venmax Drugs and Pharmaceuticals Limited

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Statement of Assets and Liabilities as at 31st March 2026

(Rs. In Lakhs)

Particulars	Notes	As at 31st March 2026, Audited	As at 31st March 2025, Audited
I.ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	3	3.65	4.05
(b) Capital Work-In-Progress			
(c) Intangible Assets			
(d) Financial Assets			
(i) Non-Current Investments			
(ii) Trade and Other Receivables			
(iii) Long Term Loans and Advances			
(d) Deferred Tax Assets (Net)			
(e) Other Non-Current Assets			
Non-Current Assets		3.65	4.05
(2) Current Assets			
(a) Inventories	4	99.88	5.75
(b) Financial Assets			
(i) Investments			
(ii) Trade and Other Receivables	5	143.00	95.26
(iii) Cash and Cash Equivalents	6	122.36	248.24
(iv) Other Financial Assets	7	734.97	161.00
(c) Other Current Assets	8	516.14	2.67
Current Assets		1616.36	512.91
Total Assets		1620.02	516.96
I. EQUITY AND LIABILITIES			
(1) Equity			
(a) Share Capital	9	1158.29	523.89
(b) Other Equity	10	253.33	(82.70)
Equity		1411.62	441.19
(2) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Long Term Borrowings	11(a)	4.96	4.96

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
 CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

(b) Provisions			
(c) Deferred Tax Liabilities (Net)	12	0.10	0.10
(d) Other Non-current Liabilities			
Non-Current Liabilities		5.06	5.06
(3) Current Liabilities			
(a) Financial Liabilities			
- Short term Borrowings	11(b)	28.13	0.00
-Other Financial Liabilities	13	1.81	0.85
(i) Trade Payables			
Micro and small enterprises			
Other than micro and small enterprises	14	167.73	62.87
(b) Short Term Provisions	15	3.81	0.70
(c) Other Current Liabilities	16	1.86	6.29
Current Liabilities		203.3	70.7
Total Liabilities		1620.02	516.96

Place: Hyderabad
Date: 14th May 2026

For Venmax Drugs and Pharmaceuticals Limited

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Cash Flow Statement for the Year ended 31st March 2026

(Rs. In Lakhs)

PARTICULARS	As at 31st March 2026	As at Mar 31, 2025
	Audited	Audited
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit as per Profit & Loss A/c	27.70	(1.41)
Adjustment for:		
Depreciation	0.40	0.64
Other comprehensive income	-	-
Loss on Sale / Discard of Intangible Assets (Net)	-	1.89
Net Operating Profit Before Working Capital	28.10	1.12
Changes		
Adjustment for:		
Trade & Other Receivables	(47.75)	(95.26)
Changes in inventory	(94.13)	(5.75)
Other Current Assets	(513.48)	(1.36)
Trade Payables	104.86	52.53
Other Financial liabilities	0.96	(10.82)
Other current liabilities	(4.42)	(6.24)
Provisions	3.11	(2.24)
Other Financial Asset	(573.97)	(161.00)
Net Cash from Operating Activities	(1096.74)	(229.02)
Direct taxes paid	2.87	0
Net Cash from Operating Activities	(1099.61)	(229.02)
B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-	-
Sale of Fixed assets	-	-
Net Cash from Investing Activities	-	-
C) CASH FLOW FROM FINANCING ACTIVITIES		
Share application money pending allotment	951.60	507.26
Share Application money pending allotment money returned	-6.00	
Proceeds from long/short term borrowings	28.13	-30.25
Repayment of borrowings		
Net Cash from Financing Activities	973.73	477.01
Net Increase in Cash & Cash Equivalents	-125.88	247.99
Add: Opening Cash & Cash Equivalents	248.24	0.25
Cash and Cash equivalents at the end of the year	122.36	248.24

Place: Hyderabad
Date: 14th May 2026

For Venmax Drugs and Pharmaceuticals Limited

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

INDEPENDENT AUDITOR'S REPORT

**TO THE BOARD OF DIRECTORS OF
VENMAX DRUGS AND PHARMACEUTICALS LIMITED**

Report on the Audit of Annual Financial Results

1. We have audited the accompanying Statement of Financial Results of **VENMAX DRUGS AND PHARMACEUTICALS Limited** ("the company") for the Quarter & Year ended March 31, 2026 ("the Statement"), attached hereto being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us these Financial Results:
 - (i) are presented in the accordance with the requirement of Regulation 33 of the Listing Regulation in this regard; and
 - (ii) gives true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards (IND-AS) and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended 31st March 2026.

3. BASIS FOR OPINION

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

4. Managements and Board of Directors' Responsibilities for the Annual Financial Results

These Annual financial results have been prepared on the basis of the Annual financial statements.

The Company's Management and Board of Directors are responsible for the preparation of these Annual Financial Results that give a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

5. Auditors Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the financial results made by the Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the annual financial results, including the disclosures, and whether the annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

6. Other Matters

The annual financial results include the results for quarter ended March 31, 2026, being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For PPKG & Co.,
Chartered Accountants
FRN -09655S

Girdhari Lal Toshniwal
Girdhari Lal Toshniwal
Partner
Membership -205140
UDIN - 26205140DJFYQW5142



Place: Hyderabad
Date: 14/05/2026

May 14, 2026

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

Scrip Code: 531015

Subject: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligation and Disclosure Requirements), Regulations, 2015

This is to confirm that M/s PPKG & Co, Chartered Accountants (Firm Registration No.009565S) Statutory Auditors of the Company, have given the Audit Report with Unmodified Opinion on the Audited Financial for the year ended 31st March, 2026.

This Declaration is given in compliance to the Regulation 33(3)(d) of the SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, as amended by SEBI (Listing Obligations Disclosure Requirements) (Amendment) Regulation 2016, read with Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Kindly take the above information on record and oblige.

Thanking You

Yours Faithfully

for **Venmax Drugs & Pharmaceuticals Limited**

Venkata Rao Sadhanala
Managing Director
DIN: 02906370